CRISPR Therapeutics AG
CRSP
$53.52
$1.883.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 598.29% | 68.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 598.29% | 68.75% | |||
| Cost of Revenue | -6.20% | -16.55% | |||
| Gross Profit | 13.99% | 17.09% | |||
| SG&A Expenses | 2.15% | -6.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.11% | -15.37% | |||
| Operating Income | 11.86% | 15.84% | |||
| Income Before Tax | 26.13% | 6.08% | |||
| Income Tax Expenses | 14.42% | 36.64% | |||
| Earnings from Continuing Operations | 25.85% | 5.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.85% | 5.88% | |||
| EBIT | 11.86% | 15.84% | |||
| EBITDA | 12.24% | 15.54% | |||
| EPS Basic | 26.20% | 6.65% | |||
| Normalized Basic EPS | 28.49% | 6.85% | |||
| EPS Diluted | 26.21% | 6.64% | |||
| Normalized Diluted EPS | 28.49% | 6.85% | |||
| Average Basic Shares Outstanding | 0.48% | 0.82% | |||
| Average Diluted Shares Outstanding | 0.48% | 0.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||